===
Issuer: CureVac / Key word(s): Patent
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
2024-07-11 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

. New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas
Therapeutics
. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March
25, 2025, by European Patent Office in the context of the German patent litigation
. UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A
tail technology) began July 10; judgement expected later in 2024

TÜBINGEN, Germany/BOSTON, USA - July 11, 2024 - CureVac N.V. (Nasdaq: CVAC) ("CureVac"), a global biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today
announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies
including the U.S., UK and Germany.
The U.S. trial against Pfizer/BioNTech will take place on March 3, 2025, before the U.S. District Court of the Eastern
District of Virginia. A previously issued court recommendation to stay the proceedings for all 10 U.S. patents was
withdrawn. The recommendation had followed a motion by Acuitas Therapeutics to intervene, sever and stay proceedings
based on co-owner and co-inventorship claims. It was resolved after both companies reached a settlement in April 2024,
which provided Acuitas licenses to several patents, including three out of four disputed U.S. patents. These three
patents have been withdrawn from the U.S. patent litigation against Pfizer/BioNTech. In return, Acuitas acknowledges
that CureVac is the sole owner of the disputed patents.
Litigation in Europe will continue March 25, 2025, with a hearing on the validity of EP 3 708 668 B1 (split poly-A tail
technology), before the Opposition Division of the European Patent Office. The infringement action in relation to this
patent was previously suspended pending the validity determination by the European Patent Office. In the German patent
litigation against Pfizer/BioNTech, the settlement with Acuitas Therapeutics led to the withdrawal of two utility
models covering equivalent claims to the three patents withdrawn in the United States. As previously announced, a
hearing before the infringement court of Düsseldorf covering the European patent EP 4 023 755 B1 (split poly-A tail
technology) and the utility model DE 20 2021 004 130 U1 (COVID-19 vaccine design), is scheduled for September 10, 2024.
Furthermore, a trial in the UK has started on July 10, 2024. It is based on a declaration of non-infringement and
request for revocation by Pfizer/BioNTech in the UK for the two CureVac patents EP 3 708 668 B1 and EP 4 023 755 B1
(split poly-A-tail technology). CureVac counterclaimed for infringement. A judgement is expected later in 2024. The
trial for the further involved patent EP 1 857 122 B1 (G/C enrichment technology) will be set for a later time point.
About CureVac
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger
RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and
manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key
underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently
laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA
technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized
cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the
human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in
the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media Contact
Patrick Perez, Junior Manager Public Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1831
M: +49 151 14 115247
patrick.perez@curevac.com
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the
United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions,
expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned
subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or
future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential
efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway,
growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology
such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would,"
"could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the
company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not
place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the
worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and
clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and
collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in
current and proposed legislation, regulations and governmental policies, pressures from increasing competition and
consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of
operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability
to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in
litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the
statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company's control and could cause its actual results to differ materially from those it
thought would occur. The forward-looking statements included in this press release are made only as of the date hereof.
The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as
required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and
Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      CureVac 

Friedrich-Miescher-Str. 15
72076 Tübingen
Germany
EQS News ID: 1944401

End of News EQS News Service

===
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1944401&application_name=news&site_id=dow_jones%7e%7e%7e43f1f857-252a-44a4-bbde-f4a32f6a5492

END) Dow Jones Newswires

July 11, 2024 07:01 ET (11:01 GMT)